Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NC318

Monoclonal antibody · Antagonist of Siglec-15 · developed by NextCure

Phase 2 Most advanced trial
NXTC Developer
2 Registered trials

What is NC318?

NC318 is a humanized IgG1 monoclonal antibody that binds Siglec-15 on tumor-associated macrophages and certain tumor cells. It is being studied in solid tumors, including non-small cell lung cancer, breast cancer, head and neck squamous cell carcinoma, endometrial cancer, melanoma, colorectal cancer, urothelial carcinoma and cholangiocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
Siglec-15
Mechanism
Antagonist of Siglec-15
Pathways
tumor-associated macrophage survival and differentiation, T-cell response inhibition, tumor angiogenesis
Therapy area
Oncology
Developer
NextCure, Inc. (NXTC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04699123 Phase 2 Advanced Non-small Cell Lung Cancer Active not recruiting NXTC
NCT03665285 Phase 1/2 Advanced or Metastatic Solid Tumors Completed NXTC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Non-small Cell Lung CancerAdvanced or Metastatic Solid TumorsBreast CancerCholangiocarcinomaCRCEndometrial CancerHead and Neck Squamous Cell CarcinomaLung CancerMelanomaUrothelial Carcinoma

Other drugs acting on SIGLEC15

More from NextCure

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.

Follow NXTC, the company behind NC318

See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NXTC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.